To verify whether the COX7A1 expression has the same effect on the OS and DFS of GC patients as our immune response ssGSEA score, we performed survival analysis of COX7A1. As we expected, in TCGA + GSE84437 and GSE15459 datasets, the OS of GC patients with high expression of COX7A1 was significantly worse than those with low expression of COX7A1 (both P < 0.001, Fig. 6E, F). This evidence concerns the gene COX7A1 and gastric cancer.